Invitrogen™ ProcartaPlex™ Human SARS-CoV-2 Variants Neutralizing Antibody Panel, 6plex

The ProcartaPlex Human SARS-CoV-2 Variants Neutralizing Antibody Panel 6plexl enables detection of neutralizing anti-SARS-CoV-2 antibodies in serum and plasma. The assay enables direct comparison of the neutralizing potential of antibodies towards the original wild type virus and five variants (B.1.1.529 (o), B.1.617.2 (δ), P.1 (γ), B.1.351 (β), and B.1.1.7 (α)) in a single well using Luminex xMAP technology. Simultaneous detection of neutralizing anti-SARS-CoV-2 antibodies in one assay not only saves time but allows comparative measurement to provide a complete, holistic data set of neutralizing activity in serum or plasma samples.

Unlike most ProcartaPlex kits that utilize matched antibody pairs to detect proteins of interest, this serological assay is designed with SARS-CoV-2 S1 wild type or variant proteins conjugated to the bead. Samples or controls are added and the antibodies bind to the conjugated proteins. This is a competitive assay where biotinylated ACE2 is used as detection reagent. Biotinylated ACE2 binds to the spike protein on the beads when not blocked by bound neutralizing antibodies. Streptavidin-phycoerythrin (PE) is added and the signal is indirectly proportional to the amount of specific neutralizing antibodies present. Negative controls will give the highest signal, while neutralizing antibodies in the sample or the positive control will reduce the signal.

The panel is provided in a ready-to-use format and the total incubation time is three hours. The kit comes with two vials of positive controls. Serum and plasma samples are recommended to be diluted 1:100. It is not combinable with simplexes or other panels.

Target list [bead region]

Neutralizing antibodies towards:

• SARS-CoV-2 S1 B.1.1.529 (o), [57]
• SARS-CoV-2 S1 B.1.617.2 (δ), [56]
• SARS-CoV-2 Spike B.1.617.2 P.1 (γ), [53]
• SARS-CoV-2 S1 B.1.351 (β), [33]
• SARS-CoV-2 S1 B.1.1.7 (α), [29]
• SARS-CoV-2 S1 (wt), [15]